PT  - JOURNAL ARTICLE
AU  - Glei, Dana A.
AU  - Weinstein, Maxine
TI  - In the Midst of a Pandemic, Introverts May Have a Mortality Advantage
AID  - 10.1101/2022.05.24.22275508
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.24.22275508
4099  - http://medrxiv.org/content/early/2022/05/25/2022.05.24.22275508.short
4100  - http://medrxiv.org/content/early/2022/05/25/2022.05.24.22275508.full
AB  - Extroverts may enjoy lower mortality than introverts under normal circumstances, but the relationship may be different during an airborne pandemic when social contact can be deadly. We used data for midlife Americans surveyed in 1995-96 with mortality follow-up through December 31, 2020 to investigate whether the association between extroversion and mortality changed during the COVID-19 pandemic. We hypothesized that excess mortality during the pandemic will be greater for extroverts than for introverts. Results were based on a Cox model estimating age-specific mortality controlling for sex, race/ethnicity, the period trend in mortality, and an additional indicator for the pandemic period (Mar-Dec 2020). We interacted extroversion with the pandemic indicator to test whether the relationship differed between prepandemic and pandemic periods. Prior to the pandemic, extroversion was associated with somewhat lower mortality (HR=0.93 per SD, 95% CI 0.88-0.97), but the relationship reversed during the pandemic: extroverted individuals appeared to suffer higher mortality than their introverted counterparts, although the effect was not significant (HR=1.20 per SD, 95% CI 0.93-1.54).Extroversion was associated with greater pandemic-related excess mortality (HR=1.20/0.93=1.29 per SD, 95% CI 1.00-1.67). Compared with someone who scored at the mean level of extroversion, mortality rates prior to the pandemic were 10% lower for a person who was very extroverted (i.e., top 12% of the sample at Wave 1), while they were 12% higher for someone who was very introverted (i.e., 11th percentile). In contrast, mortality rates during the pandemic appeared to be higher for very extroverted individuals (HR=1.15, 95% CI 0.77-1.71) and lower for those who were very introverted (HR=0.70, 95% CI 0.43-1.14) although the difference was not significant because of limited statistical power. In sum, the slight mortality advantage enjoyed by extroverts prior to the pandemic disappeared during the first 10 months of the COVID-19 pandemic. It remains to be seen whether that pattern continued into 2021-22. We suspect that the mortality benefit of introversion during the pandemic is largely a result of reduced exposure to the risk of infection, but it may also derive in part from the ability of introverts to adapt more easily to reduced social interaction without engaging in self-destructive behavior (e.g., drug and alcohol abuse). Introverts have been training for a pandemic their whole lives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institute on Aging (P01 AG020166, U19AG051426) and the Graduate School of Arts and Sciences, Georgetown University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://doi.org/10.3886/ICPSR02760.v19 and https://midus-study.github.io/public-documentation/Mortality/Core/MIDUS_Core_MortalityCauseData_N2124_20220310.sav.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://doi.org/10.3886/ICPSR02760.v19 and https://midus-study.github.io/public-documentation/Mortality/Core/MIDUS_Core_MortalityCauseData_N2124_20220310.sav. The Stata do-files used for the analysis are available upon reasonable request to the authors. https://doi.org/10.3886/ICPSR02760.v19 https://midus-study.github.io/public-documentation/Mortality/Core/MIDUS_Core_MortalityCauseData_N2124_20220310.sav